{"id":56268,"date":"2026-02-04T21:17:36","date_gmt":"2026-02-04T13:17:36","guid":{"rendered":"https:\/\/flcube.com\/?p=56268"},"modified":"2026-02-04T21:17:37","modified_gmt":"2026-02-04T13:17:37","slug":"novo-nordisk-sales-reach-dkk-309-billion-on-glp-1-and-obesity-surge","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56268","title":{"rendered":"Novo Nordisk Sales Reach DKK 309 Billion on GLP\u20111 and Obesity Surge"},"content":{"rendered":"\n<p><strong>Novo Nordisk<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE:\u202fNVO<\/a>) reported 2025 global sales of <strong>DKK\u202f309\u202fbillion (USD\u202f48.9\u202fbillion)<\/strong>, representing <strong>10% year\u2011on\u2011year (YOY) growth<\/strong> at constant exchange rates (CER). Operating profit rose <strong>6%<\/strong> to <strong>DKK\u202f122.7\u202fbillion (USD\u202f20.2\u202fbillion)<\/strong>, driven by strong performance in GLP\u20111 diabetes therapies and obesity treatments, while rare disease revenue grew 9%.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2025 Result<\/th><th>YOY Growth (CER)<\/th><th>USD Conversion<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Sales<\/strong><\/td><td>DKK\u202f309\u202fB<\/td><td>+10%<\/td><td>USD\u202f48.9\u202fB<\/td><\/tr><tr><td><strong>Operating Profit<\/strong><\/td><td>DKK\u202f122.7\u202fB<\/td><td>+6%<\/td><td>USD\u202f20.2\u202fB<\/td><\/tr><tr><td><strong>Diabetes &amp; Obesity Care<\/strong><\/td><td>DKK\u202f289.5\u202fB<\/td><td>+10%<\/td><td>\u2014<\/td><\/tr><tr><td><strong>Obesity Therapy Revenue<\/strong><\/td><td>\u2014<\/td><td>+31%<\/td><td>\u2014<\/td><\/tr><tr><td><strong>GLP\u20111 Diabetes Revenue<\/strong><\/td><td>\u2014<\/td><td>+6%<\/td><td>\u2014<\/td><\/tr><tr><td><strong>Rare Disease Revenue<\/strong><\/td><td>DKK\u202f19.6\u202fB<\/td><td>+9%<\/td><td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-geographic-revenue-breakdown\">Geographic Revenue Breakdown<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>2025 Revenue (DKK)<\/th><th>YOY Growth<\/th><th>Key Highlights<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>173.2\u202fB<\/td><td>+8%<\/td><td>340B rebate reversal impact<\/td><\/tr><tr><td><strong>Europe &amp; Canada<\/strong><\/td><td>66.1\u202fB<\/td><td>+16%<\/td><td>Strong growth across markets<\/td><\/tr><tr><td><strong>Emerging Markets<\/strong><\/td><td>30.4\u202fB<\/td><td>+8%<\/td><td>Stable performance<\/td><\/tr><tr><td><strong>Asia\u2011Pacific<\/strong><\/td><td>20.7\u202fB<\/td><td>+25%<\/td><td>High growth region<\/td><\/tr><tr><td><strong>Greater China<\/strong><\/td><td>18.7\u202fB<\/td><td>+5%<\/td><td>Weight\u2011loss therapy +182%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-china-market-performance\">China Market Performance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Greater China Revenue:<\/strong> DKK\u202f18.658\u202fbillion (+5% YOY)<\/li>\n\n\n\n<li><strong>Weight\u2011Loss Therapy Sales:<\/strong> DKK\u202f824\u202fmillion (<strong>+182%<\/strong>)<\/li>\n\n\n\n<li><strong>Semaglutide Sales:<\/strong> DKK\u202f796\u202fmillion (<strong>+314% surge<\/strong>)<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> China remains key growth driver despite overall moderate growth rate<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-2026-outlook-amp-strategic-impact\">2026 Outlook &amp; Strategic Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Operating Profit Guidance:<\/strong> <strong>+11% growth<\/strong> projected for 2026, positively impacted by <strong>USD\u202f4.2\u202fbillion reversal<\/strong> of sales rebate provisions related to the US 340B Drug Pricing Program<\/li>\n\n\n\n<li><strong>GLP\u20111 Market Dominance:<\/strong> Ozempic and Wegovy continue to drive obesity and diabetes segments globally<\/li>\n\n\n\n<li><strong>Portfolio Expansion:<\/strong> Rare disease growth of 9% demonstrates diversified revenue base<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding revenue growth, operating profit projections, and market performance for 2026. Actual results may differ due to competitive dynamics, regulatory changes, and currency fluctuations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/ca260203-q4-2025.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of ca260203-q4-2025.\"><\/object><a id=\"wp-block-file--media-baa091ac-c90d-4237-adca-71ab31b44909\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/ca260203-q4-2025.pdf\">ca260203-q4-2025<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/ca260203-q4-2025.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-baa091ac-c90d-4237-adca-71ab31b44909\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk (NYSE:\u202fNVO) reported 2025 global sales of DKK\u202f309\u202fbillion (USD\u202f48.9\u202fbillion), representing 10% year\u2011on\u2011year (YOY) growth&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56269,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,148,860],"class_list":["post-56268","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-novo-nordisk","tag-nyse-nvo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk Sales Reach DKK 309 Billion on GLP\u20111 and Obesity Surge - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk (NYSE:\u202fNVO) reported 2025 global sales of DKK\u202f309\u202fbillion (USD\u202f48.9\u202fbillion), representing 10% year\u2011on\u2011year (YOY) growth at constant exchange rates (CER). Operating profit rose 6% to DKK\u202f122.7\u202fbillion (USD\u202f20.2\u202fbillion), driven by strong performance in GLP\u20111 diabetes therapies and obesity treatments, while rare disease revenue grew 9%.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56268\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Sales Reach DKK 309 Billion on GLP\u20111 and Obesity Surge\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk (NYSE:\u202fNVO) reported 2025 global sales of DKK\u202f309\u202fbillion (USD\u202f48.9\u202fbillion), representing 10% year\u2011on\u2011year (YOY) growth at constant exchange rates (CER). Operating profit rose 6% to DKK\u202f122.7\u202fbillion (USD\u202f20.2\u202fbillion), driven by strong performance in GLP\u20111 diabetes therapies and obesity treatments, while rare disease revenue grew 9%.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56268\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T13:17:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-04T13:17:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0405.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56268#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56268\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Sales Reach DKK 309 Billion on GLP\u20111 and Obesity Surge\",\"datePublished\":\"2026-02-04T13:17:36+00:00\",\"dateModified\":\"2026-02-04T13:17:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56268\"},\"wordCount\":263,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56268#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0405.webp\",\"keywords\":[\"Finanical Reports\",\"Novo Nordisk\",\"NYSE: NVO\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56268#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56268\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56268\",\"name\":\"Novo Nordisk Sales Reach DKK 309 Billion on GLP\u20111 and Obesity Surge - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56268#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56268#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0405.webp\",\"datePublished\":\"2026-02-04T13:17:36+00:00\",\"dateModified\":\"2026-02-04T13:17:37+00:00\",\"description\":\"Novo Nordisk (NYSE:\u202fNVO) reported 2025 global sales of DKK\u202f309\u202fbillion (USD\u202f48.9\u202fbillion), representing 10% year\u2011on\u2011year (YOY) growth at constant exchange rates (CER). Operating profit rose 6% to DKK\u202f122.7\u202fbillion (USD\u202f20.2\u202fbillion), driven by strong performance in GLP\u20111 diabetes therapies and obesity treatments, while rare disease revenue grew 9%.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56268#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56268\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56268#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0405.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0405.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk Sales Reach DKK 309 Billion on GLP\u20111 and Obesity Surge\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56268#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Sales Reach DKK 309 Billion on GLP\u20111 and Obesity Surge\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Sales Reach DKK 309 Billion on GLP\u20111 and Obesity Surge - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk (NYSE:\u202fNVO) reported 2025 global sales of DKK\u202f309\u202fbillion (USD\u202f48.9\u202fbillion), representing 10% year\u2011on\u2011year (YOY) growth at constant exchange rates (CER). Operating profit rose 6% to DKK\u202f122.7\u202fbillion (USD\u202f20.2\u202fbillion), driven by strong performance in GLP\u20111 diabetes therapies and obesity treatments, while rare disease revenue grew 9%.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56268","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Sales Reach DKK 309 Billion on GLP\u20111 and Obesity Surge","og_description":"Novo Nordisk (NYSE:\u202fNVO) reported 2025 global sales of DKK\u202f309\u202fbillion (USD\u202f48.9\u202fbillion), representing 10% year\u2011on\u2011year (YOY) growth at constant exchange rates (CER). Operating profit rose 6% to DKK\u202f122.7\u202fbillion (USD\u202f20.2\u202fbillion), driven by strong performance in GLP\u20111 diabetes therapies and obesity treatments, while rare disease revenue grew 9%.","og_url":"https:\/\/flcube.com\/?p=56268","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-04T13:17:36+00:00","article_modified_time":"2026-02-04T13:17:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0405.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56268#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56268"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Sales Reach DKK 309 Billion on GLP\u20111 and Obesity Surge","datePublished":"2026-02-04T13:17:36+00:00","dateModified":"2026-02-04T13:17:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56268"},"wordCount":263,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56268#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0405.webp","keywords":["Finanical Reports","Novo Nordisk","NYSE: NVO"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56268#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56268","url":"https:\/\/flcube.com\/?p=56268","name":"Novo Nordisk Sales Reach DKK 309 Billion on GLP\u20111 and Obesity Surge - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56268#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56268#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0405.webp","datePublished":"2026-02-04T13:17:36+00:00","dateModified":"2026-02-04T13:17:37+00:00","description":"Novo Nordisk (NYSE:\u202fNVO) reported 2025 global sales of DKK\u202f309\u202fbillion (USD\u202f48.9\u202fbillion), representing 10% year\u2011on\u2011year (YOY) growth at constant exchange rates (CER). Operating profit rose 6% to DKK\u202f122.7\u202fbillion (USD\u202f20.2\u202fbillion), driven by strong performance in GLP\u20111 diabetes therapies and obesity treatments, while rare disease revenue grew 9%.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56268#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56268"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56268#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0405.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0405.webp","width":1080,"height":608,"caption":"Novo Nordisk Sales Reach DKK 309 Billion on GLP\u20111 and Obesity Surge"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56268#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Sales Reach DKK 309 Billion on GLP\u20111 and Obesity Surge"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0405.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56268","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56268"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56268\/revisions"}],"predecessor-version":[{"id":56271,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56268\/revisions\/56271"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56269"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56268"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56268"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56268"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}